Souhaitez-vous accéder aux communiqués récents ?

“The totality of data from the PROTECT study demonstrates FILSPARI is effective, safe and has an important place in the IgAN treatment landscape ..."

Pune, India, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Point-of-care molecular diagnostics include portable devices, and assays & kits used to detect and diagnose diseases in human samples, such as...

The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.

Dublin, Sept. 06, 2023 (GLOBE NEWSWIRE) -- The "EGFR Tests Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and...

PHOENIX, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Dignity Health St. Joseph’s Hospital and Medical Center has launched a new initiative to address race-based algorithms in early diagnosis of chronic kidney...

Dublin, Nov. 15, 2022 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Global Market Report 2022, By Product, By End User, By Clinical Application" report has been added to ResearchAndMarkets.com's offering....

CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in...

CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...

-- Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Greater China -- -- Collaboration accelerates and expands global development of Blueprint Medicines’...

Novel TKI compound with dual selective targeting of mutant forms of EGFR and BTKMore than 600 patients have been treated with the compound across studies, with over 200 patients in the completed...